.
The Norwegian Institute of Public Health is currently considering the use of a Nuvaxovid protein vaccine in Norway.
- The vaccine may be suitable for primary immunization in adults who have not yet been vaccinated. Or as a refreshment for people who have already been vaccinated with the other COVID-19 vaccines we have used in Norway. This is Sara Viksmoen Watle's head doctor in FHI's infection control and vaccine department.
Nuvaxovid by Novavax is not yet available in Norway, but it was approved by the European Medicines Agency (EMA) before Christmas. According to the Norwegian Medicines Agency, its protective effect against serious complications and death is 90 percent.
Unlike other vaccines, this is a protein-based vaccine.
Scientists hope that such vaccines will be able to provide longer-term protection for antibodies, and thus more people will take them.
Source: NTB
(AP Photo / Charles Krupa)
Read our next article: How to Find Your Own Coronavirus Certificate in Norway
